Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRUIN-CLL-314: pirtobrutinib versus ibrutinib in CLL/SLL
2023-507699-38-00Phase 3Authorised
- Sponsor
- Loxo Oncology
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Pirtobrutinib with Ibrutinib (2 arms). Primary endpoint: Overall response rate. Planned start Aug 2022; status: authorised.
02
Drugs
pirtobrutinibibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2023-507699-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507699-38-00.